Eli Lilly to Acquire Calytrix Bio in Deal Worth Up to $1.5 Billion
Photo: Darron Cummings/AP/TT

Eli Lilly to Acquire Calytrix Bio in Deal Worth Up to $1.5 Billion

The American pharmaceutical group Eli Lilly has agreed to acquire biotechnology company Calytrix Bio for up to $1.5 billion, equivalent to around SEK 15 billion.

Advertisement

Calytrix Bio develops treatments for various blood disorders, mainly essential thrombocythemia and myelofibrosis.

Eli Lilly, which makes the weight-loss drug Zepbound, is a major competitor of Denmark’s Novo Nordisk.

Calytrix Bio was founded in 2025 by JP Morgan Life Sciences Private Capital.

In this story
AuthorTT News AgencyEnglish edition by Sweden Herald, adapted for our readers
Was this useful?

What do you think?

Keep readingmore from Business

All